You are here

Press Release Archive

 
- Pfizer and Nektar Reach Agreement on Exubera(R)

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera® and Nektar’s innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development. Under the terms of the agreement, Nektar will receive a one-time payment of $135 million from

 
- Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events

(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) was more effective than simvastatin (20 mg–40 mg) in reducing the risk of multiple cardiovascular events in patients with a history of heart attacks in the Incremental Decreases through Aggressive Lipid Lowering (IDEAL) clinical trial. Cardiovascular events included heart attack, stroke, and cardiac revascularization

 
- Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function

(BUSINESS WIRE)--Pfizer announced today that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study,

 
- New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association

(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium) Tablets will be presented next week at the Annual Scientific Sessions of the American Heart Association. SPARCL Trial A new post-hoc analysis (planned after the study completed) of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study looked

 
- Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact

(BUSINESS WIRE)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010. The decision — which resulted from a patent challenge by generic manufacturers Ranbaxy Laboratories Limited and Basics GmbH — has no immediate commercial

 
- Pfizer Announces Retirement of Vice Chairman David L. Shedlarz

(BUSINESS WIRE)--Pfizer said today that after a 31-year career Vice Chairman David L. Shedlarz will retire from the company at the end of this year. Mr. Shedlarz’s contributions to the company include helping to shape the strategic direction that drove Pfizer’s growth to pharmaceutical industry leadership; fifteen years of service on Pfizer’s senior management committee and ten as its Chief Financial Officer; and

 
- Pfizer Declares a 29-Cent Fourth-Quarter, 2007, Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent fourth-quarter, 2007, dividend on the company's common stock, payable December 4, 2007, to shareholders of record at the close of business on November 9, 2007. Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The fourth-quarter

 
- Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent

(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010. The patent was challenged by generic manufacturer Lek Pharmaceuticals D.D., and is one of four separate challenges to the calcium salt patent by generic

 
- Pfizer Reports Third-Quarter 2007 Results; Reconfirms 2007 and 2008 Revenue and Adjusted Diluted EPS(1) Guidance

(BUSINESS WIRE)--Pfizer: ($ in millions, except per-share amounts) Third Quarter Year to Date 2007 2006

 
- Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care

(BUSINESS WIRE)--Pfizer Inc (www.pfizer.com) and Sermo (www.sermo.com), the nation’s largest online physician community, today announced a strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Sermo is a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide new insights

 
- Research Reveals New Trends and Best Practices among Multinational Corporations Engaging in International Corporate Volunteering Programs

(BUSINESS WIRE)--The Brookings Institution’s Initiative on International Volunteering and Service, FSG Social Impact Advisors and Pfizer Inc, today released a landmark independent report researched and written by FSG on the state of international corporate volunteering (ICV) programs. The report details the landscape of this emerging trend among multinationals, the perceived business value of ICV and community impact, and the business

 
- Pfizer Invites Public to View and Listen to Webcast of October 18 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Thursday, October 18. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2007 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit

 
- Dr. Martin Mackay Named President of Pfizer Global Research and Development

(BUSINESS WIRE)--Pfizer today named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and bioinnovation center under the direction of scientist and entrepreneur Dr. Corey Goodman; and named Dr. Briggs Morrison, who held senior research and development positions at Merck, as its new Head of Clinical Development for the PGRD pipeline. “As the

 
- Pfizer Hires New Vice President and Chief Talent Officer

(BUSINESS WIRE)--Pfizer announced today that Dr. Tanya Clemons, a senior executive with extensive experience in leadership and organization change at Microsoft and IBM, will join Pfizer as vice president and Chief Talent Officer in November. Dr. Clemons will report to Mary McLeod, the senior vice president for Worldwide Talent Development and Human Resources. She will be a member of the Human Resources Leadership Team and Pfizer

 
- Canadian Federal Court Upholds Viagra Patent

(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s second medical use patent covering Viagra would be infringed by Apotex’ proposed generic product. The court granted the company’s application for an order preventing Apotex from launching a generic version of Viagra until expiration of Canadian Patent No. 2,163,446 in 2014. The decision is subject to

 
- Pfizer Recognized as Leader in Addressing Climate Change

(BUSINESS WIRE)--Pfizer Inc announced today that in recognition for its approach to improving the environment, the company was named to the Climate Disclosure Leadership Index (CDLI) by the Carbon Disclosure Project (CDP), a not-for-profit coalition of more than 315 global investors. Pfizer was one of 68 Fortune 500 companies -- and the only pharmaceutical company -- named in the CDLI, a prestigious honor roll for global corporations

 
- Two New Directors Elected to Pfizer Board

(BUSINESS WIRE)--Pfizer Inc announced today the election of Suzanne Nora Johnson and James M. Kilts to the Pfizer Board of Directors effective September 27, 2007. Ms. Johnson, 50, retired as Vice Chairman of The Goldman Sachs Group Inc. in January 2007. She had been with the firm for 21 years in roles ranging from the head of health care investment banking to the head of global research and the Chairman of the Global Markets

 
- New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer

(BUSINESS WIRE)--Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with advanced gastric cancer. Additionally, data from phase I studies provide information on the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies in the treatment of hormone-refractory prostate cancer (HRPC) and advanced

 
- Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients

(BUSINESS WIRE)--Pfizer Inc announced today that the European Commission (EC) has approved Celsentri® (maraviroc). Treatment-experienced HIV patients in the EU can soon benefit from the first CCR5 antagonist and only oral entry inhibitor. Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 virus detectable

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.